id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-287338-pws42iay	Gendelman, Omer	Continuous hydroxychloroquine or colchicine therapy does not prevent infection with SARS-CoV-2: Insights from a large healthcare database analysis	2020-05-05		.txt	text/plain	2016	107	46	As such, in this study, we investigated whether a chronic baseline use of anti-inflammatory medications (namely, hydroxychloroquine and colchicine) could provide a potentially beneficial effect in preventing or, at least partially, mitigating the burden of the SARS-CoV-2 infection. In the present study, we have utilized "real-world data" to explore the associations between subjects positive for SARS-COV-2, different underlying co-morbidities and medications, which were not administered for anti-viral treatment purposes. In a population-based study evaluating the clinical characteristics of 1,482 patients hospitalized with COVID-19 in the USA [19] the majority of patients were males (54.4%) with a similar pattern of underlying comorbidities, most commonly hypertension (49.7%), followed by obesity (48.3%), DM (28.3%), and cardiovascular disease (27.8%). Concerning the alleged anti-viral activities of hydroxychloroquine [23] and its potential protective role against infections [24] , the existing scholarly literature reports contrasting findings even though to date no RCT has shown an unequivocal advantage in preventing or improving the major outcomes in COVID-19 patients [25, 26] .	./cache/cord-287338-pws42iay.txt	./txt/cord-287338-pws42iay.txt